CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
BRISBANE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2nd at 2:25 PM ET.
A live audio webcast of the Cantor Fitzgerald Global Healthcare Conference presentation will be available online from the investor relations section of the CareDx website at https://investors.caredxinc.com or through the following link http://wsw.com/webcast/cantor10/cdna/. The webcast replay of the presentation will be available approximately one hour following the conclusion of the live presentation and will be available on the Company’s website for 90 days.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
CONTACTS:
Sasha King
Chief Marketing Officer, CareDx Inc.
415-287-2393
sking@caredx.com
Michael Bell
Chief Financial Officer, CareDx Inc.
415-287-2324
mbell@caredx.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
